Acrodermatitis chronica atrophicans
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Acrodermatitis chronica atrophicans Classification and external resources | |
| ICD-10 | L90.4 |
|---|---|
| ICD-9 | 701.8 |
| DiseasesDB | 32940 |
| eMedicine | derm/4 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Acrodermatitis chronica atrophicans (ACA) also known as Pick-Herxheimer disease, is a skin rash indicative of the third or late stage of European Lyme borreliosis.
ACA is a dermatological condition that takes a chronically progressive course and finally leads to a widespread atrophy of the skin. Involvement of the peripheral nervous system is often observed, specifically polyneuropathy.
This progressive skin process is due to the effect of continuing active infection with the spirochete Borrelia afzelii. B afzelii is the predominant pathophysiology, but may not be the exclusive, etiologic agent of ACA. Borrelia garinii, has also been detected.
History
The first record of ACA was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it.
Herxheimer and Hartmann described it in 1902 as a "tissue paper" like cutaneous atrophy.
Presentation
The rash caused by ACA is most evident on the extremities or limbs beginning with an inflammatory stage with bluish red discoloration and cutaneous swelling and concluding several months or years later with an atrophic phase. Sclerotic skin plaques may also develop.
As ACA progresses the skin begins to wrinkle.
Prognosis and Treatment
The course of ACA is long-standing, from a few to several years, and it leads to extensive atrophy of the skin and, in some patients, to the limitation of upper and lower limb joint mobility.
The outlook is good if the acute inflammatory stage of ACA is treated adequately. The therapeutic outcome is difficult to assess in patients with the chronic atrophic phase, in which many changes are only partially reversible.
Physicians should use serologic and histologic examination to confirm the diagnosis of ACA. Treatment consists of antibiotics including doxycycline and penicillin for up to four weeks in the acute case.
See also
External links
WikiDoc Research Resources for Acrodermatitis chronica atrophicans | |
|---|---|
| Articles on Acrodermatitis chronica atrophicans | Most recent articles on Acrodermatitis chronica atrophicans • Most cited articles on Acrodermatitis chronica atrophicans • Review articles on Acrodermatitis chronica atrophicans • Articles on Acrodermatitis chronica atrophicans in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Acrodermatitis chronica atrophicans | Powerpoint slides on Acrodermatitis chronica atrophicans • Images of Acrodermatitis chronica atrophicans • Photos of Acrodermatitis chronica atrophicans • Podcasts & MP3s on Acrodermatitis chronica atrophicans • Videos on Acrodermatitis chronica atrophicans |
| Evidence Based Medicine Regarding Acrodermatitis chronica atrophicans | Cochrane Collaboration on Acrodermatitis chronica atrophicans • Bandolier on Acrodermatitis chronica atrophicans • TRIP on Acrodermatitis chronica atrophicans |
| Cost Effectiveness of Acrodermatitis chronica atrophicans | Cost Effectiveness of Acrodermatitis chronica atrophicans |
| Clinical Trials Involving Acrodermatitis chronica atrophicans | Ongoing Trials on Acrodermatitis chronica atrophicans at Clinical Trials.gov • Trial results on Acrodermatitis chronica atrophicans • Clinical Trials on Acrodermatitis chronica atrophicans at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Acrodermatitis chronica atrophicans | US National Guidelines Clearinghouse on Acrodermatitis chronica atrophicans • NICE Guidance on Acrodermatitis chronica atrophicans • NHS PRODIGY Guidance • FDA on Acrodermatitis chronica atrophicans • CDC on Acrodermatitis chronica atrophicans |
| Textbook Information on Acrodermatitis chronica atrophicans | Books and Textbook Information on Acrodermatitis chronica atrophicans |
| Pharmacology Resources on Acrodermatitis chronica atrophicans | Dosing of Acrodermatitis chronica atrophicans • Drug interactions with Acrodermatitis chronica atrophicans • Side effects of Acrodermatitis chronica atrophicans • Allergic reactions to Acrodermatitis chronica atrophicans • Overdose information on Acrodermatitis chronica atrophicans • Carcinogenicity information on Acrodermatitis chronica atrophicans • Acrodermatitis chronica atrophicans in pregnancy • Pharmacokinetics of Acrodermatitis chronica atrophicans • |
| Genetics, Pharmacogenomics, and Proteinomics of Acrodermatitis chronica atrophicans | Genetics of Acrodermatitis chronica atrophicans • Pharmacogenomics of Acrodermatitis chronica atrophicans • Proteomics of Acrodermatitis chronica atrophicans |
| Newstories on Acrodermatitis chronica atrophicans | Acrodermatitis chronica atrophicans in the news • Be alerted to news on Acrodermatitis chronica atrophicans • News trends on Acrodermatitis chronica atrophicans |
| Commentary on Acrodermatitis chronica atrophicans | Blogs on Acrodermatitis chronica atrophicans |
| Patient Resources on Acrodermatitis chronica atrophicans | Patient resources on Acrodermatitis chronica atrophicans • Discussion groups on Acrodermatitis chronica atrophicans • Patient Handouts on Acrodermatitis chronica atrophicans • Directions to Hospitals Treating Acrodermatitis chronica atrophicans • Risk calculators and risk factors for Acrodermatitis chronica atrophicans |
| Healthcare Provider Resources on Acrodermatitis chronica atrophicans | Symptoms of Acrodermatitis chronica atrophicans • Causes & Risk Factors for Acrodermatitis chronica atrophicans • Diagnostic studies for Acrodermatitis chronica atrophicans • Treatment of Acrodermatitis chronica atrophicans |
| Continuing Medical Education (CME) Programs on Acrodermatitis chronica atrophicans | CME Programs on Acrodermatitis chronica atrophicans |
| International Resources on Acrodermatitis chronica atrophicans | Acrodermatitis chronica atrophicans en Espanol • Acrodermatitis chronica atrophicans en Francais |
| Business Resources on Acrodermatitis chronica atrophicans | Acrodermatitis chronica atrophicans in the Marketplace • Patents on Acrodermatitis chronica atrophicans |
| Informatics Resources on Acrodermatitis chronica atrophicans | List of terms related to Acrodermatitis chronica atrophicans |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
